Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across ...
WATERTOWN, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon ...
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in ...
ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in ...
I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Acrivon Therapeutics (ACRV). The reason why I want to go over this biotech next is because I ...
ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies ...
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the ...
"Our data at AACR illustrate several of the broad capabilities of our AP3 platform and the power of employing this precision proteomics-based approach in both drug discovery and drug development," ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback